JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garza, R. D. L.
Right arrow Articles by Cunningham, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garza, R. D. L., II
Right arrow Articles by Cunningham, K. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*COCAINE

Vol. 292, Issue 2, 610-617, February 2000

The Effects of the 5-Hydroxytryptamine1A Agonist 8-Hydroxy-2-(di-n-propylamino)tetralin on Spontaneous Activity, Cocaine-Induced Hyperactivity and Behavioral Sensitization: A Microanalysis of Locomotor Activity1

Richard De La Garza, II2 and Kathryn A. Cunningham

Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas.

The influence of the 5-hydroxytryptamine1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (DPAT) on locomotor hyperactivity induced by the acute and chronic administration of cocaine was assessed. Horizontal activity was measured in the periphery and center of an open field test enclosure equipped with photobeams; vertical activity was also recorded. Peripheral hyperactivity induced by an acute administration of cocaine (10 or 20 mg/kg) was significantly enhanced by 0.2 mg/kg DPAT. In contrast, central and vertical activities were reduced in a dose-related manner by DPAT (0.1 and 0.2 mg/kg); DPAT also suppressed central (0.2 mg/kg) and vertical (0.1 and 0.2 mg/kg) activities when administered alone. Similar observations were made on day 1 of chronic treatment with DPAT (0, 0.1, or 0.2 mg/kg) injected 15 min before an injection of cocaine (0, 10, or 15 mg/kg) administered twice daily for 7 days. By day 7 of repeated DPAT treatment, sensitization of DPAT-evoked peripheral activity developed, which contrasted with tolerance to the central and vertical hypoactivity evoked by DPAT. Sensitization developed to the repeated treatment with 15 mg/kg cocaine but not 10 mg/kg cocaine. Interestingly, enhancements of all activity measures were observed between days 1 and 7 in rats cotreated with DPAT plus either dose of cocaine. This sensitization to DPAT plus cocaine was expressed on challenge with DPAT and cocaine but not with cocaine alone. The present study implies that the stimulation of 5-hydroxytryptamine1A receptors is capable of modulating the hyperactivity evoked by cocaine, possibly via modulation of the mesoaccumbens dopamine circuit thought to mediate the behavioral effects of cocaine.


1 This work was supported by National Institute on Drug Abuse Grants DA05708, DA06511 (K.A.C.), and DA05638 (R.D.). Portions of this research were presented at the annual meeting of the Society for Neuroscience, Miami, FL, November, 1994, and at the annual meeting of the College on the Problems of Drug Dependence, Scottsdale, AZ, June, 1995. This research was presented to the Graduate School of the Biomedical Sciences at the University of Texas Medical Branch in partial fulfillment of the requirements for the degree of Doctor of Philosophy.

2 Present address: Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06520.


0022-3565/00/2922-0610$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. Newman-Tancredi, D. Cussac, Y. Quentric, M. Touzard, L. Verriele, N. Carpentier, and M. J. Millan
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes
J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 815 - 822.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. G. Bankson and K. A. Cunningham
3,4-Methylenedioxymethamphetamine (MDMA) as a Unique Model of Serotonin Receptor Function and Serotonin-Dopamine Interactions
J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 846 - 852.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
M. J. Millan
Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 853 - 861.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.